The FDA said Aug. 9 tests of samples of a Merck diabetes drug detected substances that can cause cancer, and to avoid shortages, the department said it would allow increased levels of the carcinogen by nearly 150 percent.
Read the full post on Becker's Hospital Review - Healthcare News
